Skip to main content
Clinical Trials/EUCTR2006-006086-16-ES
EUCTR2006-006086-16-ESActive, not recruitingNot Applicable

The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis.A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.Eficacia y seguridad de 2 g de ranelato de estroncio en el tratamiento de la osteoporosis en hombre. Estudio prospectivo, multicéntrico, internacional, doble ciego, controlado frente a placebo con una duración del tratamiento de 2 años y el análisis principal del estudio tras 1 año. - MALEO

aboratorios Servier S.L.0 sites221 target enrollmentStarted: October 25, 2007Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Enrollment
221

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Male

Inclusion Criteria

  • . The following BMD criterion:
  • - Mean lumbar spine BMD lower than 0.840g/cm² or femoral neck BMD lower than 0.600g/cm² measured by Hologic apparatus
  • - Mean lumbar spine BMD lower than 0.949g/cm² or femoral neck BMD lower than 0.743 g/cm² measured by Lunar apparatus
  • . Caucasian males of at least 65 years of age (with no upper age limit)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • - Bone mineral Density T-score below -4.0 at one or more of the measured sites
  • - More than two prevalent mild and/or moderate osteoporotic vertebral fractures
  • - Severe osteoporotic vertebral fractures

Investigators

Sponsor
aboratorios Servier S.L.

Similar Trials

Active, not recruiting
Not Applicable
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis.A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year. - MALEOmale osteoporosisMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-006086-16-BEInstitut de Recherches Internationales Servier221
Active, not recruiting
Not Applicable
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis.A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year. - MALEOmale osteoporosisMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-006086-16-SEInstitut de Recherches Internationales Servier221
Active, not recruiting
Phase 1
The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.Osteoporosis in menMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-004717-17-CZInstitut de Recherches Internationales Servier221
Active, not recruiting
Not Applicable
The efficacy and safety of 2g strontium ranelate in the treatment of osteoporosis in men. A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year.Osteoporosis in menMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-004717-17-EEInstitut de Recherches Internationales Servier221
Active, not recruiting
Not Applicable
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis.A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year. - MALEOmale osteoporosisMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-006086-16-IEInstitut de Recherches Internationales Servier221